Fabian Borghese

Fabian leads the development, qualification, and validation of potency assays for rAAV-based GT products at UCB. He earned is PhD in molecular virology in 2015 (De Duve Institute, Belgium), then joined the Belgian biotech company, Imcyse, where he worked on an innovative vaccine-based technology for the treatment of auto-immune diseases (type I diabetes, multiple sclerosis, …). He then joined Celyad, where he contributed to the development of autologous and allogeneic CAR T cell candidates targeting haematological cancers. Fabian joined UCB in 2022 to lead the development of cell-based potency assays for recombinant AAV product candidates. Since 2023, Fabian is a core contributor to the Biophorum GT Potency Strategy workstream.